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A B S T R A C T
Background and objectives: Mucopolysaccharidosis type VI (MPS VI) is a rare, autosomal recessive lysosomal
storage disorder caused by deficient enzymatic activity of N-acetyl galactosamine-4-sulphatase, which is caused
by mutations in the arylsulphatase B (ARSB) gene. To date, 163 different types of mutations in the ARSB have
been reported. However, the full mutation spectrum in the MPS VI phenotype is still not known. The aim of this
study was to perform molecular testing of the ARSB gene in the patient and his family members to confirm MPS
VI.
Methods: Molecular characterisation of the ARSB gene was performed using Sanger sequencing. We studied a
child suspected of having MPS VI and 16 other relatives.
Results: We identified a C-to-T transition resulting in an exchange of the Arg codon 160 for a premature stop
codon (R160*, in exon 2). The transition was in CpG dinucleotides.
Interpretation and conclusions: The study provided some insights into the genotype-phenotype relationship in
MPS VI and the importance of genetic testing when diagnosing MPS, which is not a mandatory test for the
diagnosis and only very occasionally performed. Additionally, we present here the history of a family with
confirmed MPS VI, which is extremely rare especially in south-eastern Poland. What is more, the position where
the mutation is located is very interesting because it is the region of CpG, which is the site of the methylation
process. Thus, this opens the possibility of a new approach indicating the involvement of an epigenetic me-
chanism that should be examined in the context of the pathomechanism of MPS.
1. Introduction
Mucopolysaccharidosis type VI (MPS VI, OMIM: 253200) also
known as Maroteaux–Lamy syndrome is a rare autosomal recessive
lysosomal storage disorder caused by deficiencies in the activity of N-
acetyl galactosamine-4-sulfatase (4-sulfatase, arylsulphatase B, ARSB,
EC 3.1.6.12). ARSB is an enzyme critical for the degradation of glyco-
saminoglycans (GAGs), dermatan sulphate and chondroitin sulphate.
Molecular defects that cause MPS VI lead to an accumulation of GAGs in
connective tissue, lysosomes and urinary excretion of partially de-
graded dermatan sulphate (DS) [1,2].
In general, for MPS, a prevalence of approximately 0.22 cases per
100,000 births was found for MPS I, while for MPS II, the prevalence
was estimated at 0.45 cases per 100,000 births; for MPS IV A and B, at
0.14 cases in 100,000 births; and for MPS VI, at 0.03 cases per 100,000
births. Fig. 1 demonstrates the prevalence rates for MPS [6]. The in-
cidence of MPS VI varies greatly between populations, ranging from 0
in Northern Ireland to 20 per 100,000 live births in Monte Santo county
in Northeast Brazil. In Central and Eastern Europe, the incidence rate
ranges from 0.0363 to 0.64 per 100,000 live births in Poland and Li-
thuania, respectively. It is the rarest form of mucopolysaccharidosis in
Poland [3–6].
It is believed that the relatively high prevalence in Lithuania and
other Eastern Europe countries is caused by the founder effect with a
high carrier frequency of the p.(Arg152Trp) mutation in the ARSB gene.
MPS VI has a wide variety of clinical phenotypes depending on the
https://doi.org/10.1016/j.ymgmr.2020.100658
Received 29 July 2020; Received in revised form 3 October 2020; Accepted 4 October 2020
⁎ Corresponding author.
E-mail address: barbara.zapala@uj.edu.pl (B. Zapała).
Molecular Genetics and Metabolism Reports 25 (2020) 100658
Available online 28 October 2020
2214-4269/ © 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
T
patient. These include growth retardation, coarse facial features, ske-
letal deformities, hepatosplenomegaly, corneal opacity, dysostosis
multiplex, joint stiffness, and respiratory and cardiac abnormalities. In
contrast to other types of mucopolysaccharidosis, patients with MPV VI
exhibit normal mental development. Three common clinical forms of
MPS VI are observed: severe or infantile, intermediate or juvenile, and
mild or adult. The majority of patients with the infantile form die in
childhood due to cardiopulmonary complications. In contrast, patients
with the adult form of MPS VI have less severe clinical symptoms and
their life-span often reaches the seventh or eighth decade [1,2].
MPS VI is determined by mutations in the arylsulfatase B (ARSB)
gene. The ARSB gene is located on chromosome 5q11-q13, spanning
less than 440 kb. It contains 8 exons which encode a polypeptide con-
sisting of 533 amino acids with a signal peptide of 37 amino acids.
According to the records provided by the Human Gene Mutation
Database (HGMD, www.hgmd.cf.ac.uk) 163 mutations have been
identified, most of them being single base, missense or nonsense var-
iations. Most of them are unique to individual families while a few have
been attributed to the founder effect. This heterogeneity is believed to
contribute to the wide spectrum of symptoms in MPS VI patients
[7–11].
2. Clinical case study
A 14month-old male patient was admitted to our hospital suffering
from hand contracture, thought to be the result of arthritis.
The boy was from the first pregnancy, first delivery, born by cae-
sarean section (pelvic fetal position, IUGR) in the 37th week, Apgar
score 9/10, birth weight 2570 g, with features of intrauterine dys-
trophy. Perinatal tests revealed GBS infection in the mother, in-
trauterine infection was excluded in the newborn. In the 4th week of
life, hip dysplasia was diagnosed, and the boy remained under the care
of the orthopedic clinic (initially diapers, then a Pavlik harness) and
was undergoing rehabilitation. In the 2nd month of life, left-sided in-
guinal hernia developed. In approx. The 6–7th month, the mother no-
ticed a “hump” of the spine (thoracic lumbar vertebrae, Th-L, border-
line). From about 7th month, there were contractures in the knee joints.
In addition, delayed motor development, and increased muscle tone
were observed during infancy. The parents were not related to one
another. The parents were young (mother 21 years old and father
24 years old) and without any clinical symptoms. There was no family
history of any illnesses.
The boy was in a good general condition. Physical examination
revealed thick facial features, a prominent forehead, narrow palate,
contractures in the knee and hip joints and in the interphalangeal joints
of hands, umbilical hernia, left-sided inguinal hernia, funnel chest, in-
creased muscular tone, and dysmorphic features.
The patient was referred to the Rheumatology Outpatient Clinic
(which has extensive experience as it also functions as the Center of
Rare Diseases) due to contractures in the joints of the hands, knees and
abnormal gait. The boy was suspected to be suffering from MPS I or VI.
The most common type of MPS II among the Polish population was
excluded, based on our clinical experience and the observed phenotype
as well as family history. In the family history, there were no incidences
of MPS II, which is an X-linked recessive disease. The observed
symptom of the disease was a mild stiffness of the finger joints. The
results of basic laboratory tests were within the reference intervals for
his age. Electrophoresis of excreted GAG revealed dermatan sulfate in
the serum and urine. Ultrasound of the abdomen showed the liver size
at the upper norm limit with a homogeneous parenchyma and moder-
ately enlarged spleen with a uniform echogram of the parenchyma.
Ultrasound of the hip joints revealed no exudate, synovial hyperplasia,
and no increased vascular flow. The joint capsule was adjacent. A clear
thickening up to 7.7mm of the joint capsule on both sides and sig-
nificantly increased echogenicity of the joint capsules were found. Both
joints were symmetric, the femoral head round, without visible pa-
thology, and the periarticular space was without pathology [12,13]. We
did not observe any other clinical manifestations such as cardiac in-
volvement, corneal clouding or upper airway obstruction. Growth re-
tardation was observed as shown in Fig. 2. The patient was treated with
enzyme replacement therapy, ERT (Naglazyme).
Since the patient presented with characteristic clinical symptoms of
MPS VI, abnormal development of the spine in the thorax-lumbar part
and normal intellectual function, we decided to perform a molecular
study of the ARSB gene as there was a suspicion that it might be MPS VI.
Blood samples were collected from the patient, his parents, grand-
parents and the parents' siblings.
3. Molecular genetic studies
Total genomic DNA was obtained from peripheral blood collected in
EDTA. Isolation was performed using a NucleoSpin Blood Kit
(Macherey Nagel). Sequences of primers specific to the ARSB gene were
used according to Petry et al. as previously described [Petry et al.,
2005]. Polymerase chain reaction (PCR) was used to amplify exons 1–8
and the adjacent intronic regions of the ARSB gene. The amplification
was performed using a FastStart PCR Master Kit (ROCHE Diagnostics).
The PCR products were purified with a NucleoSpin Gel and PCR Clean-
up (Macherey Nagel) and sequenced with a BigDye Terminator
v.3.1 Cycle Sequencing Kit (Life Technologies, Foster City, CA, USA).
The products of cycle sequencing were purified of unbound fluorescent
dyes with a BigDye XTerminator Purification Kit (Life Technologies,
Foster City, CA, USA) and separated on a 3130xl Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). The sequences were ana-
lysed using the AB DNA Sequencing Analysis Software v.5.2. (Applied
Biosystems) and then were compared to the ARSB gene reference (NCBI
GeneBank Reference Sequence Accession Numbers: NM_000046.5 and
ENSEMBL database Accession Numbers: ENST00000264914.9).
4. Ethics statement




At first, we identified a C-to-T transition, resulting in an exchange of
the Arg codon 160 for a premature stop codon [p.(Arg160*)], in exon 2
in the patient (Fig. 3). The variant was presented in the homozygous
state in the patient. This variant has been previously reported and is
recorded in The Human Gene Mutation Database (HGMD) as causing
Fig. 1. Relative rates of mucopolysaccharidoses in Poland (including 392 pa-
tients). Data according to Jurecka et al. [6].
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the MPS VI phenotype. We next performed genetic testing in the pa-
tient's parents. We also identified the presence of the same variant in
the heterozygous state in both parents, which confirmed the diagnosis
of MPS VI which is inherited autosomally recessively.
5.2. Other family members
Among the relatives on the father's side of the family, the same
variant was identified in the heterozygous state. On the mother's side,
only her father did not have the variant. The family history with fre-
quency of Arg160* is presented in Fig. 4.
6. Discussion
In this report, we present the history of MPS VI diagnosed in a Polish
family. Confirmation of this type of MPS was unexpected as Poland has
the lowest prevalence of MPS VI.
The patient was suspected to be suffering from either MPS I or VI.
Based on our clinical experience and knowing the clinical symptoms
and diagnostic results, we excluded MPS II (the most common in the
Polish population). The boy presented several characteristic clinical
symptoms of MPS VI, mostly related to skeletal deformities without
mental retardation. The first observed symptom in the boy was a mild
stiffness of the finger joints and then growth retardation.
This is the first case of MPS VI diagnosed in the south-eastern region
of Poland. The highest prevalence of MPS VI was reported in Russia,
Kazakhstan, Central and Eastern Europe and Belarus [3,6]. The patient
was the first child of young and healthy parents and was born to a
family without a history of MPS or any past illnesses. However, fol-
lowing genetic testing, interviews with the parents revealed that many
ancestors on both sides of the family were born in territories occupied
by Russia during the World War II. Another aspect of this case is that
the mutation that we identified may be the founder variant for MPS VI
in the Russian population.
No specific ethnic group has been associated with an increased risk
of MPS VI. However, it may be the case that some populations have
increased frequencies of specific mutations causing the disease. Petry
et al., described the deletion of 23 nucleotides at position 1533 of the
ARSB gene, which is very characteristic for the Brazilian population
[14,15]. The same variant is very common (with a frequency 23% of
alleles) in Portuguese MPS VI patients [15]. We mention this here be-
cause, based on the literature, we can speculate that there are founder
mutations linked to various ethnic populations. This is not a new fact,
but grouping and exploring these founder mutations could help to
characterise the genetics of different types of MPS. There are unique
common mutations in different genes that are responsible for different
types of MPS. Some common mutations in a particular MPS may di-
rectly correspond to the high prevalence of that particular MPS in a
certain region or ethnic group. It is known that different types of MPS
are distributed with different frequencies in different regions on the
world. The exact characterisation of mutations that are associated with
the birth prevalence of certain types of MPS and the countries or even
the regions over the world could be very helpful in diagnosing the
disease and especially in confirming the phenotype. Moreover, it may
help clinicians in assessing the relative risks and benefits of the cur-
rently available therapies. The low prevalence of MPS among countries,
especially Poland, and the large number of mutations as well as in-
consistent phenotype testing limit the ability to predict phenotype from
genotype.
The variant that we identified in the Polish family was [p.
(Arg160*)]. This variant was identified for the first time in 1994 in
Germany, where it was encountered 7 times. This variant has already
been found in diverse populations and ethnic groups such as Belarusian,
Indian, Italian, Russian, Spanish and Taiwanese patients [16–21]. This
substitution results from a transition in a CpG dinucleotide region. This
is the second very interesting point in our study. Until now, the most
Fig. 2. Associations of age and z scores of weight (A), height (B), and body mass
index (BMI) (C) of the patient.
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unique variants identified in the ARSB gene were missense (~59%);
followed by small deletions (~13%), nonsense (~12%), splice site or
intronic variants (~5%), small duplications (~3%), large deletions
(~3.0%) and stop-loss mutations (~1.0%). In our study, we identified a
C-to-T transition at the 478 nucleotide position within a CpG dinu-
cleotide. It is also known that the mutation rate varies throughout the
genome in a contextual fashion [22]. It was estimated that ~24% of
missense or nonsense variants in the ARSB gene are transitions in a CpG
dinucleotide [23]. The nonsense variant that we confirmed in the pa-
tient is described as one of a total of seven nonsense mutations reported
in the gene. Among them, p.(Arg160*) is one of two (with p.(Arg315*))
of the transitions located in CpG nucleotides consisting of ~28% which
are predicted to change the gene's activity and are strongly related to
the phenotype's severity [22]. ***.
Knowing that 10–60% of SNPs that cause human diseases result
from transitions at CpG dinucleotides, we can speculate that CpG me-
thylation may have important implications for the etiology of not only
MPS VI, but also of all types of MPS. It may provide new insight into the
etiology of the disease which has a wide heterogeneity on both phe-
notype and genotype levels. It could be worth evaluating the relation-
ship between methylation status and CpG hotspot mutations in the
whole genome in MPS VI patients, which has not previously been stu-
died. In patients diagnosed with MPS type II and IV, it was demon-
strated that the methylation pattern in iduronate-2-sulfatase (IDS) and
lysosomal N-acetylgalactos-amine-6-sulfatase (GALNS) genes causing
the disease correlated with the likelihood of mutation. Methylation
regulates gene expression and can play a crucial role in the occurrence
of MPS VI-causing mutations [24]. The variant that we confirmed in our
patient has been suggested to be a mutational hotspot in the ARSB gene
[18,20].
The third and the final aspect that we want to discuss here is the
importance of the genotype-phenotype relationship that should be in-
cluded at the beginning of the diagnostic process of MPS VI. Nowadays,
the diagnosis of mucopolysaccharidosis is generally established based
on a combination of clinical symptoms and laboratory tests. The pa-
tients may show growth retardation, coarse facial features, skeletal
deformities, frequent upper-airway infections, enlarged liver and
spleen, hearing loss, joint stiffness, or coarse hair. All of these symptoms
and signs suggests a mucopolysaccharidosis but do not provide a spe-
cific diagnosis. The first step in MPS VI diagnosis is the assessment of
urinary GAGs excretion with dermatan sulphate and chondroitin sul-
phate being compounds excreted in high amount. Both quantitative and
qualitative analysis of urinary GAGs is performed. A positive result is
usually followed by measurement of the ARSB enzyme activity in
Fig. 3. ARSB sequencing electropherograms showing [p.(Arg160*)] variant (indicated by the frame) in the patient and his parents in comparison to a healthy control
as a reference.
Fig. 4. History of the family. The patient is indicated by the black arrow. A
symbol with a question mark “?” indicates an individual who did not undergo
clinical evaluation and genetic testing.
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leucocytes and fibroblasts being considered optimal samples [25]. Al-
though the biochemical tests are sufficient to diagnose MPS VI, they do
not allow for correlation between enzyme activity and clinical pheno-
type. Due to the high frequency of broad compound heterogeneity and
incomplete identification of polymorphisms, the correlation between
genotype and phenotype, and prediction of severity is very limited. This
lack of reliability means that it is not possible to appropriately manage
the disease based on genotype at this time. Here, we would like to
emphasise the high importance of molecular testing, which contributes
to the establishment of the genotype-phenotype relationship in this
disease. As mentioned above, our patient did not have all of the specific
symptoms of the disease, his parents were young and healthy, and there
was no family history of the disease.
Thus, in this paper, we present not only the case study, but espe-
cially the high value of molecular testing in the context of diagnosing
mucopolysaccharidosis and the genotype-phenotype relationship. In
MPS patients, early intervention with ERT, which can preserve or re-
store function by removing excess material accumulated in the lyso-
some, is very important. The therapeutic potential of ERT is possible
only when the diagnosis is performed accurately. The genetic diagnosis
allows for rapid treatment initiation and also for genetic counselling.
The physical condition of our patient on the day of hospitalisation was
very critical. After molecular diagnosis, and ERT treatment, within two
years, he was able to function normally with healthy children of his age.
In reporting this case, we would like to emphasise the importance of
molecular diagnosis related to a proper treatment decision and to a
delayed disease progression (in this case, even reversing clinical man-
ifestation of the disease), and also to publish this specific clinical de-
scription of the patient with MPS VI from the Polish population, which
may help in better understanding the genotype-phenotype interactions.
MPS VI is characterised by its severity, broad clinical spectrum, and
high level of genetic diversity displayed in individuals. For most var-
iants in the ARSB gene (about 45%) there is not enough evidence in the
databases and literature for their classification and pathogenicity. The
systematic reporting and classification of alleles pathogenic for the
disease may be very helpful in reducing the time consumed during di-
agnosis, and also in reducing the ethical complications, based on our
example, in which MPS VI has the lowest frequency in the Polish po-
pulation.
Declaration of Competing Interest
The authors report no financial or other conflict of interest relevant
to the subject of this article.
Acknowledgments
This work was reviewed by McGregor Language School. This work
was supported by the BioMarin Pharmaceutical Inc.
References
[1] E.F. Neufeld, J. Muenzer, The mucopolysaccharidoses, in: C.R. Scriver,
A.L. Beaudet, W.S. Sly, D. Valle (Eds.), The Metabolic and Molecular Basis of
Inherited Disease, McGraw-Hill, New York, 2001, pp. 3421–3452.
[2] V. Valayannopoulos, H. Nicely, P. Harmatz, S. Turbeville, Mucopolysaccharidosis
VI, Orphanet J. Rare Dis. 5 (2010) 5.
[3] F. Baehner, C. Schmiedeskamp, F. Krummenauer, et al., Cumulative incidence rates
of the mucopolysaccharidoses in Germany, J. Inherit. Metab. Dis. 28 (2005)
1011–1017.
[4] A. Golda, A. Jurecka, A. Tylki-Szymanska, Cardiovascular manifestations of mu-
copolysaccharidosis type VI (Maroteaux-Lamy syndrome), Int. J. Cardiol. 158
(2011) 6–11.
[5] A. Jurecka, E. Zakharova, L. Cimbalistiene, N. Gusina, V. Malinova, A. Rozdzynska-
Swiatkowska, A. Golda, A. Kulpanovich, G. Kaldenovna Abdilova, E. Voskoboeva,
A. Tylki-Szymanska, Mucopolysaccharidosis type VI in Russia, Kazakhstan, and
central and Eastern Europe, Pediatr. Int. 56 (2014) 520–525.
[6] A. Jurecka, A. Ługowska, A. Golda, B. Czartoryska, A. Tylki-Szymańska, Prevalence
rates of mucopolysaccharidoses in Poland, J. Appl. Genet. 56 (2) (2015 May)
205–210.
[7] A. Jurecka, E. Piotrowska, L. Cimbalistiene, et al., Molecular analysis of mucopo-
lysaccharidosis type VI in Poland, Belarus, Lithuania and Estonia, Mol. Genet.
Metab. 105 (2012) 237–243.
[8] T. Litjens, E.G. Baker, K.R. Beckmann, C.P. Morris, J.J. Hopwood, D.F. Callen,
Chromosomal localization of ARSB, the gene for human N-acetylgalactosamine-4-
sulphatase, Hum. Genet. 82 (1989) 67–68.
[9] C.S. Bond, P.R. Clements, S.J. Ashby, C.A. Collyer, S.J. Harrop, J.J. Hopwood,
J.M. Guss, Structure of a human lysosomal sulfatase, Structure 5 (1997) 277–289.
[10] S. Modaressi, K. Rupp, K. von Figura, C. Peters, Structure of the human arylsulfatase
B gene, Biol. Chem. Hoppe Seyler 374 (1993) 327–335.
[11] C.S. Bond, P.R. Clements, S.J. Ashby, C.A. Collyer, S.J. Harrop, J.J. Hopwood,
J.M. Guss, Structure of a human lysosomal sulfatases, Structure 5 (1997) 277–289.
[12] Z. Żuber, A. Jurecka, A. Różdżyńska-Świątkowska, A. Migas-Majoch, A. Lembas,
B. Kieć-Wilk, A. Tylki-Szymańska, Ultrasonographic features of hip joints in
Mucopolysaccharidoses type I and II, PLoS One 10 (4) (2015 Apr 29) e0123792, ,
https://doi.org/10.1371/journal.pone.0123792 (eCollection 2015).
[13] Z. Żuber, A. Owczarek, M. Sobczyk, A. Migas-Majoch, D. Turowska-Heydel,
A. Sternal, J. Michalczak, J. Chudek, Establishing percentile charts for hip joint
capsule and synovial cavity thickness in apparently healthy children, Pediatr.
Rheumatol. Online J. 15 (1) (2017 Jan 31) 8, https://doi.org/10.1186/s12969-017-
0136-6.
[14] P.D. Stenson, M. Mort, E.V. Ball, K. Shaw, A. Phillips, D.N. Cooper, The human gene
mutation database: building a comprehensive mutation repository for clinical and
molecular genetics, diagnostic testing and personalized genomic medicine, Hum.
Genet. 133 (2014) 1–9.
[15] M.F. Petry, T. Dieter, M. Burin, R. Giugliani, S. Leistner, Identification of a novel
mutation in the ARSB gene that is frequent among Brazilian MPS VI patients, Genet
Test7 (2003) 347–349.
[16] E. Garrido, A. Chabás, M.J. Coll, M. Blanco, C. Domínguez, D. Grinberg,
B. Cormand, Identification of molecular defects in Spanish and Argentinian mu-
copolysaccharidosis VI (Maroteaux–Lamy syndrome) patients, including 9 novel
mutations, Mol. Genet. Metab. 92 (1–2) (2007) 122–130.
[17] A. Jurecka, E. Piotrowska, L. Cimbalistiene, N. Gusina, A. Sobczyńska,
B. Czartoryska, A. Tylki-Szymańska, Molecular analysis of mucopolysaccharidosis
type VI in Poland, Belarus, Lithuania and Estonia, Mol. Genet. Metab. 105 (2)
(2012) 237–243.
[18] P.K. Kantaputra, H. Kayserili, Y. Guven, W. Kantaputra, M.C. Balci, P. Tan-paiboon,
A. Dalal, Clinical manifestations of 17 patients affected with mucopolysaccharidosis
type VI and eight novel ARSB mutations, Am. J. Med. Genet. A 164A (6) (2014)
1443–1453.
[19] A. Thümler, E. Miebach, C. Lampe, S. Pitz, W. Kamin, C. Kampmann, E. Mengel,
Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI:
a case series.Journal of, Inherit. Metab. Dis. 35 (6) (2012) 1071–1079.
[20] E. Voskoboeva, D. Isbrandt, K. vonFigura, X. Krasnopolskaya, C. Peters, Four novel
mutant alleles of the arylsulfatase B gene in two patients with intermediate form of
mucopolysaccharidosis VI(Maroteaux–Lamysyndrome), Hum. Genet. 93 (3) (1994)
259–264.
[21] M.F. Petry, K. Nonemacher, J.C. Sebben, I.V. Schwartz, A.C. Azevedo, M.G. Burin,
A.R. de Rezende, C.A. Kim, R. Giugliani, S. Leistner-Segal, Mucopolysaccharidosis
type VI: identification of novel mutations on the arylsulphatase B gene in south
American patients, J. Inherit. Metab. Dis. 28 (2005) 1027–1034.
[22] R. Tomanin, L. Karageorgos, A. Zanetti, M. Al-Sayed, M. Bailey, N. Miller,
H. Sakuraba, J.J. Hopwood, Mucopolysaccharidosis type VI (MPS VI) and molecular
analysis: review and classification of published variants in the ARSB gene, Hum.
Mutat. 39 (2018) 1788–1802, https://doi.org/10.1002/humu.23613.
[23] C. Coulondre, J.H. Miller, P.J. Farabaugh, GilbertW, Molecular basis of base sub-
stitution hotspots in Escherichia coli, Nature 274 (1978) 775–780.
[24] S. Tomatsu, K. Sukegawa, G.G. Trandafirescu, M.A. Gutierrez, T. Nishioka,
S. Yamaguchi, T. Orii, R. Froissart, I. Maire, A. Chabas, A. Cooper, P. Di Natale,
A. Gal, A. Noguchi, W.S. Sly, Differences in methylation patterns in the methylation
boundary region of IDS gene in hunter syndrome patients: implications for CpG hot
spot mutations, Eur. J. Hum. Genet. 14 (2006) 838–845.
[25] R. Giugliani, P. Harmatz, J.E. Wraith, Management guidelines for mucopoly-
saccharidosis VI, Pediatrics. 120 (2007) 405–418, https://doi.org/10.1542/peds.
2006-2184.
B. Zapała, et al. Molecular Genetics and Metabolism Reports 25 (2020) 100658
5
